Navigation Links
Hard To Treat Diseases (HTDS.PK) H1N1 Swine Flu Clinical Trial
Date:8/18/2009

SHENZHEN, China, Aug. 18 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com Mellow Hope, an operating subsidiary of HTDS, is pleased to report that its clinical trial is currently being processed. The company expects it will be completed by this September (Approx 60 days). The company expects the manufacturing license will be released by October or November of this year.

H1N1 (referred to as "swine flu" early on) is a new influenza virus causing illness in people. This new virus was first detected in people in the United States in April 2009. This virus is spreading from person-to-person worldwide, probably in much the same way that regular seasonal influenza viruses spread. On June 11, 2009, the World Health Organization (WHO) signaled that a pandemic of novel H1N1 flu was underway.

Terry Yuan CEO of HTDS said (sic) "With the new H1N1 virus continuing to cause illness, hospitalizations and deaths in the whole world, it is highly recommended to make preparation for a voluntary H1N1 vaccination. Mellow Hope is the only one H1N1 vaccine supplier for the overseas market from China."

The company intends to provide many further timely updates from both of its China , and Serbia based operations.

Safe Harbor Statement:

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
2. Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes
3. Cyanide Toxicity in Smoke Inhalation Victims - a Deadly but Treatable Poison
4. A New Service for Health Care Providers Who Prescribe Methadone to Treat Chronic Pain or Opioid Addiction
5. Post-treatment pain in head and neck cancer patients linked to recurrence, lower survival rate
6. Mothers Immune System May Block Fetal Treatments for Blood Diseases
7. Genetic Discovery May Improve Hepatitis C Treatment
8. New biomarker predicts response to hepatitis C treatment
9. Cooling treatment after cardiac arrest is cost-effective, Penn study shows
10. Hard To Treat Diseases (HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment.
11. MRI may be unnecessary prior to treatment in most newly diagnosed breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Santa Rosa, California (PRWEB) , ... January 24, 2017 , ... ... named Cary McNamara as chief financial officer. , “Cary’s broad financial ... individual who possesses both the strategic planning and day-to-day financial operations skills we need ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... advance to the semi-final round of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired ... its 12th year in 2017. The entrepreneurs will showcase their businesses on February ...
(Date:1/24/2017)... ... January 24, 2017 , ... His message has been heard by ... organization End Distracted Driving , Joel Feldman, has reached his biggest national audience ... in one of the top newspapers in circulation in the country, and he hopes ...
(Date:1/24/2017)... Hill, N.C. (PRWEB) , ... January 24, 2017 ... ... Trump Administration is the focus of a new report from the Frank ... Kenan-Flagler Business School. , Influential business leaders, academics and policy makers identified concrete ...
(Date:1/24/2017)... ... , ... The NewKILO JRP, a three-year project of the European Metrology Research ... (EU), was completed in May 2015. The future definition will require the unit of ... which presents some challenges to establishing traceability to the mass scale. , This ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... -- Trifecta Clinical , a leading global provider ... Ward to Vice President of Commercial Operations.  Rick ... the promotion of Ericka Atkinson to Vice ... joins Trifecta from Greenphire where he was Vice President ... positions within the healthcare industry throughout his career.  "Rick ...
(Date:1/24/2017)... Results show Gamma Knife spares normal brain tissue ... Elekta (EKTA-B.ST) today announced new data demonstrating ... a higher radiation dose compared to linear accelerator (linac)-based delivery ... complex brain tumors, were published in the Journal ... ...
(Date:1/24/2017)... , January 24, 2017 www.Financialbuzz.com ... growing industries in the United States ... in 2016. In addition, Proposition 64, the California Cannabis Legalization ... 42.87% against on November 8, 2016. This outcome means that ... use and to grow a certain amount of cannabis for ...
Breaking Medicine Technology: